Suwa M
3rd Div. Int. Med., Osaka Medical College.
Nihon Rinsho. 2000 Jan;58(1):59-63.
Newer drug therapy for patients with cardiomyopathies has been introduced with standard one. Beta-blocker therapy improves the prognosis in patients with ischemic and non-ischemic DCM and even in asymptomatic ones with LV dysfunction. The combined therapy of ACE inhibitor and angiotensin II receptor blocker, the intermittent intravenous infusion of inotropic agents and the supplement of phosphodiesterase inhibitor on induction of beta-blocker therapy also elucidate the effectiveness in DCM patients.
针对心肌病患者的新型药物疗法已与标准疗法一同推出。β受体阻滞剂疗法可改善缺血性和非缺血性扩张型心肌病患者的预后，甚至对左心室功能不全的无症状患者也有效。血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂的联合疗法、正性肌力药物的间歇性静脉输注以及在诱导β受体阻滞剂疗法时补充磷酸二酯酶抑制剂，也证明对扩张型心肌病患者有效。
